Our team is composed of scientists, entrepreneurs, and drug hunters who share a collective vision and passion for profoundly impacting
how we age.
Caitlyn (Cat) Siegman | Research Associate II
Quinn Lyon | Research Associate II
Anil Bhushan | Scientific Founder
Cat is joining the in vivo pharmacology team as a Research Associate II. She graduated from the University of Connecticut with a Bachelor of Science in Veterinary Pathology and Pathobiology. Prior to joining Deciduous, she worked as a Research Assistant or Associate Researcher at Gilead, Genentech, and Theravance. Cat enjoys skateboarding, snowboarding, surfing, and yoyoing!
Quinn Lyon graduated from the University of California, Santa Barbara with a degree in Pharmacology. As a former research technician at the Monell Chemical Senses Center at the University of Pennsylvania, he worked both with drosophila and murine models to investigate chemosensory pathways in the Zhang Lab. Quinn now supports the Deciduous in vivo pharmacology team.
Dr. Anil Bhushan is the scientific founder of Deciduous where his lab was one of the first to show the role of clearing senescent cells in models of Type 1 diabetes. The long-term goal of his research is to understand the role of tissue secretory senescent cells in aging, autoimmunity and metabolic diseases. Recently they showed that pancreatic beta cells acquire a secretome in T1D in both mice and humans and exhibit many non-cell autonomous properties. Subsequently they have identified key immune cells that can selectively eliminate senescent beta cells to halt progression of beta cell destruction to prevent T1D in mouse models. They now utilize immune modulatory targets to identify new drugs that specifically eliminate secretory senescent cells in humans.
Philippine Alba | Research Associate II
Connor Wander | Scientist
Rachel Hatano | Chief of Staff
As a research associate II, Philippine supports the in vivo team in therapeutic efficacy studies. Her passion for science began when she served as a biology tutor and undergraduate researcher at Bard College in New York, where she earned a B.A. in Biology. She brings to Deciduous animal handling and sample prep experience gained as a veterinary assistant or technician at the VCA San Francisco Veterinary Specialists or Explora BioLabs respectively. Philippine was born in France and grew up in California. She has two cats named Hazel and Bagheera.
Connor Wander, PhD, is a Research Scientist at Deciduous Therapeutics, Inc and a recent graduate from the Pharmacology Department at UNC Chapel Hill. As a co-mentored student between the Cohen and Song Labs at UNC, Connor studied glial biology, adult neurogenesis, and inhibitory neural networks in Alzheimer's Disease. His other scientific interests include the interactions between the environment, genetics, and nutrition in neurodegenerative diseases. Connor also founded Straight from a Scientist, a science education website with podcast episodes and web games on neuroscience, astrophysics, virology, and more. Outside of the sciences, Connor enjoys hobbies such as graphic design, balcony gardening, gaming, Brazilian Jiu Jitsu, paintball and caring for his bearded dragons.
Dr. Rachel Hatano was one of the first scientists at Deciduous Therapeutics, and established a range of target validation, in vitro screening, and functional characterization bioassay experiments critical to vetting novel immunotherapies. Her current role focuses on enabling the company's operations initiatives. Rachel received her PhD in Bioengineering at University of California, Merced, where she focused on cardiovascular tissue engineering & integrated cellular systems. In addition, Rachel is an advocate/active mentor for minorities in STEM programs in the Bay Area and California central valley.
Janice Lansita | Toxicology Lead
Nadia Khan | Scientist
Robin Mansukhani | CEO and Co-Founder
Dr. Janice Lansita is a board-certified toxicologist with over 16 years of experience, both in the biopharmaceutical industry and with the Food and Drug Administration (FDA). As a regulatory toxicologist, she has developed small molecule as well as biologic therapies, including monoclonal antibodies, bispecifics, fusion proteins, cytokines, cell and gene therapies, peptides, enzyme replacement therapies, and DNA/RNA based therapies for a broad range of indications (e.g., rare disease, oncology, neurology, pain, ophthalmology, and immunology). Dr. Lansita has extensive experience in the design, monitoring, and interpretation of nonclinical toxicology studies (GLP and non-GLP) and has authored the nonclinical sections of various regulatory documents, including pre-INDs, INDs/CTAs (>30), Investigator Brochures, annual reports, BLAs/NDAs, and package inserts/product labels for biopharmaceuticals. She has specialized expertise in the nonclinical development of biologic therapeutics, including pharmacologically relevant species selection, immunogenicity, immune-mediated toxicity (e.g., complement activation, anti-drug antibodies, autoimmunity, cytokine-release), surrogate animal models, immunotoxicology endpoints, study design and setting the FIH starting dose (MABEL, HNSTD, NOAEL).
Nadia Khan is a neuroscientist joining Deciduous Therapeutics to explore the therapeutic potential of clearing senescent cells to treat age-related disorders. She received her PhD at the University of Wisconsin-Madison in Avtar Roopra's lab and completed her postdoctoral training in Tristan Shuman's lab at the Mount Sinai School of Medicine in New York City. Nadia's background and experience primarily comes from studying mechanisms of disease pathology in Epilepsy, using a variety of cell, molecular, animal behavior, animal modeling, in vivo imaging and electrophysiology techniques. Nadia comes to Deciduous Therapeutics after working as a Scientist II at CODA Biotherapeutics. She is looking forward to harnessing the power of the immune system to treat human diseases.
Robin Mansukhani is CEO and Co-Founder of Deciduous Therapeutics. Previously, he co-founded and served as President & CEO of Alzeca Biosciences, an Alzheimer’s/CNS diagnostic imaging company which was supported by venture investors and the NIH. He has been an invited speaker both domestically and abroad, including TEDx. Previously Robin has worked in early stage venture capital at The Maple Fund and investment banking at Axiom Capital. In the community, he co-founded BlueStamp Engineering, an intensive, project based engineering program for high school students in NYC, San Francisco, and Palo Alto. He has also served a term in AmeriCorps. Mr. Mansukhani holds a B.S. in Biochemistry from Case Western Reserve University. He lives in San Francisco with his wife, three daughters, and indefatigable dog. He enjoys cooking and exercise, sometimes in that order.
Kristen Lorentz | COO
Aritra Bhattacharyya | Scientist
Kelly Kusche | Research Associate II
Kristen is an entrepreneurial bioengineer with a multidisciplinary background spanning biotech and pharma. Previously, Kristen co-founded and served as executive leadership for two biotech companies, Anokion and Kanyos Bio, where she played a leading role in company creation and the clinical translation of advanced therapies for autoimmune diseases. Kristen then went on to lead Search and Evaluation for Gastroenterology and Rare Diseases within the R&D Business Development team at Takeda. Kristen earned her B.S. in Biomedical Engineering from Northwestern University and her Ph.D. in Bioengineering from the Swiss Federal Institute of Technology in Lausanne (EPFL). She is an advocate for workplace inclusiveness and serves on the board of the non-profit Women in the Enterprise of Science and Technology. She enjoys travel, the great outdoors, and staying active – especially when combining all three.
Aritra Bhattacharyya is an immunologist at Deciduous Therapeutics where his team is focused on activating the immune system for clearance of senescent cells in vivo. He has finished his postdoctoral training at the University of California, San Francisco SABRE center before completing his PhD from Humboldt Universität zu Berlin, Germany, funded by Jurgen Manchot Stiftung. Both during his PhD and Postdoctoral training, he studied the roles of the myeloid and mesenchymal compartment during various lung diseases such as bacterial pneumonia, idiopathic pulmonary fibrosis, asthma, and influenza infection.
Kelly Kusche graduated from the University of California, Irvine with a Bachelor of Science degree in Pharmaceutical Sciences. After graduating, Kelly worked as a research associate at Gladstone Institutes, where she studied the use of optogenetics to extinguish OCD behaviors in mouse models. She is thrilled to be joining the in vivo research team II at Deciduous to apply and expand her pharmaceutical knowledge and laboratory experience.
Matt Duncton | Medicinal Chemistry
Dr. Matt Duncton has over 20 years of experience in medicinal chemistry with a career working in oncology, immunology, anti-infectives and neuroscience therapeutic areas at companies such as Merck, Vernalis, OSI Pharmaceuticals, ImClone Systems, Renovis, and Rigel Pharmaceuticals. Since 2016, Matt has served as an independent consultant in medicinal chemistry working with small biopharmaceutical organizations, Venture Capital groups and academia. Matt is an author/inventor on more than 90 papers and patents and his work has led to projects advancing in to human clinical trials, such as ARX-1796 (recently licensed to Pfizer), NFX-179 (currently, Phase II), RN-5327 (TRPV1 antagonist; Phase I), and a host of other IND candidates.